Results 211 to 220 of about 7,719,266 (361)

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Editorial: Clinical trial design and development in neonatal and perinatal medicine

Frontiers in Pediatrics
Mohamed E. Abdel-Latif, Mohamed E. Abdel-Latif, Mohamed E. Abdel-Latif, Yogavijayan Kandasamy, Yogavijayan Kandasamy, Yogavijayan Kandasamy, Sabita Uthaya, Sabita Uthaya, Dirk Bassler, Dirk Bassler, Jonathan M. Davis, Jonathan M. Davis   +11 more
doaj   +1 more source

An independent appraisal and re-analysis of hydroxychloroquine treatment trial for COVID-19

Swiss Medical Weekly, 2020
Katheron Intson, Sachin A. Kumar, Amy Botta, Rachael Neckels, Connie Leung, Ali Jawaid   +5 more
doaj   +1 more source

The use of complex clinical trials: a regulatory review. [PDF]

Trials
Nguyen Q, Kästel H, Hees K, Hofner B.
europepmc   +1 more source

Occurrence of Type 1 Diabetes in a Patient Enrolled in an Immunotherapy Combination Phase 1 Clinical Trial: A Case Study

, 2021
Sheena Charles, Anna Poullard
openalex   +1 more source

Evolve trial Evolve trial

Indian Heart Journal
Unknown
openaire   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Trial of Pattern Reversal Visual Evoked Response in Patients with Visual Conversion Reaction

, 2007
Mayumi Miyata, Osamu Katsumi, Megumi Oikawa, Junko Itô, Yoshitaka Miyanaga, Jiro Inouye   +5 more
openalex   +2 more sources

Decision letter for "Effectiveness of physical activity prescription by primary care nurses using health assets: A randomized controlled trial"

, 2020

openalex   +1 more source

Crucial parameters for precise copy number variation detection in formalin‐fixed paraffin‐embedded solid cancer samples

Molecular Oncology, EarlyView.
This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.
Hanne Goris, Vasiliki Siozopoulou, Léon C van Kempen, Anne Sieben, Ella Roelant, Stig Hellemans, Elyne Backx, Laure Sorber, Koen De Winne, Senada Koljenović, Karen Zwaenepoel   +10 more
wiley   +1 more source